Company news

SAB Biotherapeutics, Inc. news in 2023

SAB Biotherapeutics, Inc.'s news releases, calls and decks from 2023, newest first.

View company

SAB Biotherapeutics Announces Commencement of the HUMAN Phase 1 Clinical Trial with SAB-142, a Potential Disease-Modifying Treatment for Type 1 Diabetes

November 28, 2023

SAB Biotherapeutics Appoints Katie Ellias to the Board of Directors

November 19, 2023

SAB Biotherapeutics Announces Q3 2023 Financial Results and Provides Company Updates

November 13, 2023

SAB Biotherapeutics Announces Completion of $67.1 Million Financing to Advance Potential Disease-Modifying Treatment for Type 1 Diabetes

November 13, 2023

SAB Biotherapeutics to Present at Piper Sandler Healthcare Conference

November 8, 2023

SAB Biotherapeutics Appoints Michael G. King Jr. as Chief Financial Officer

October 23, 2023

SAB Biotherapeutics Receives Australian Approval to Commence Phase 1 Clinical Trial of SAB-142, a Potential Disease-Modifying Treatment for Type 1 Diabetes

October 18, 2023

SAB Biotherapeutics Approves Appointment of Andrew Moin to Board of Directors

October 4, 2023

SAB Biotherapeutics Announces Private Placement of up to $130 Million to Advance Development of Lead Drug Candidate for Type 1 Diabetes

October 1, 2023

SAB Biotherapeutics Provides Company Update for Q2 2023 Financial Results

August 20, 2023

SAB Biotherapeutics Presents Positive IND-Enabling GLP Toxicology Study for SAB-142, a Novel Immunotherapeutic for Type 1 Diabetes at FOCIS 2023

June 20, 2023

SAB Biotherapeutics to Present Novel Human IgG Platform with Positive Data and Breakthrough Therapy and Fast-Track Designations for Influenza Treatment at BIO 2023 International Convention

May 29, 2023

SAB Biotherapeutics Presents Virtual 2023 R&D Day Portfolio Update: Breakthrough Immunotherapy Innovations

May 18, 2023

SAB Biotherapeutics Provides Company Update for Q1 2023 Financial Results

May 15, 2023

SAB Biotherapeutics Announces First Publication of Promising Nonclinical Data for SAB-183 Against Pneumonic Plague in the Journal Antibodies

May 11, 2023

SAB Biotherapeutics Announces Progress on U.S. FDA’s Phased Review of Company’s Groundbreaking DiversitAb™ Platform

May 8, 2023

SAB Biotherapeutics Presents Positive Phase 1 and 2a Data for SAB-176 Influenza Immunotherapy at ISIRV-AVG Conference

May 3, 2023

SAB Biotherapeutics Announces Positive Results from Phase 3 Trial of SAB-185 in Patients with COVID-19 at High-Risk for Severe Complications

April 25, 2023

SAB Biotherapeutics Announces U.S. FDA Grants Breakthrough Therapy Designation to SAB-176 Influenza Immunotherapy

April 17, 2023

SAB Biotherapeutics Granted Fast Track Designation from FDA for SAB-176 Influenza Immunotherapy with High Cross-Reactivity to Multiple Strains of Influenza

April 12, 2023

SAB Biotherapeutics Announces Appointment of Erick Lucera, CFA to Board of Directors

April 3, 2023

SAB Biotherapeutics Provides Company Update for Full Year 2022

March 30, 2023

SAB Biotherapeutics Receives an Additional $8.2 Million in Closeout of DoD Contract

January 17, 2023

SAB Biotherapeutics Successfully Concludes IND-Enabling GLP Toxicology Study for SAB-142, a Novel Immunotherapeutic for Type 1 Diabetes

January 9, 2023

SAB Biotherapeutics Novel DiversitAb™ Platform Proven to Develop Anti-idiotype Antibodies to Help Treat Autoimmune Diseases

January 4, 2023

Decks in 2023